NASDAQ:LIFE - aTyr Pharma, Inc.
$0.49
 $-0.00
-0.52%
4:20PM EDT
2019-02-22
aTyr Pharma, Inc., incorporated on October 8, 2005, is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  LIFE     avg for
industry  
  avg for
sector  
42 stocks weight:  22. 04   0. 00   0. 00  
42 stocks rank:  3. 54 K 2. 00 K 1. 08 K
# analyst opinions:  1. 00   14. 68   14. 18  
mean recommendation:  3. 00   1. 96   1. 94  

quick ratio:  5. 22   5. 17   1. 75  
current ratio:  5. 38   5. 48   2. 10  

target price low:  0. 75   90. 05   118. 16  
target price avg:  0. 75   115. 98   142. 03  
target price high:  0. 75   141. 44   162. 86  
1-yr high:  3. 30   124. 28   143. 16  
last close:  0. 50   102. 75   129. 63  
50-day avg:  0. 51   98. 90   122. 76  
200-day avg:  0. 74   100. 04   123. 17  
1-yr low:  0. 38   78. 22   100. 14  
volume:  52. 46 K 2. 36 M 4. 94 M
50-day avg volume:  246. 85 K 3. 14 M 4. 85 M
200-day avg volume:  586. 59 K 3. 12 M 4. 26 M

1-day return:  2. 04 % 1. 74 % 0. 96 %
this week return:  0. 00 % -0. 72 % -0. 25 %
12-wk return:  -18. 83 % 1. 23 % -0. 75 %
52-wk return:  -83. 67 % -2. 03 % 16. 23 %

enterprise value (EV):  -23. 15 M 54. 82 B 107. 48 B
market cap:  15. 07 M 47. 12 B 97. 54 B
EBITDA:  -36. 93 M 4. 72 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 63   9. 03   16. 84  
total debt:  17. 81 M 13. 41 B 16. 70 B
debt/equity:  45. 67   41. 61   80. 63  
net income (common):  -39. 67 M 2. 34 B 3. 61 B

shares outstanding:  30. 02 M 594. 48 M 1. 22 B
shares:  20. 49 M 592. 96 M 1. 15 B
shares short:  906. 00 K 10. 54 M 11. 92 M
shares short prior month:  1. 14 M 11. 90 M 11. 87 M
short ratio:  3. 40   4. 86   3. 18  
total cash/share:  1. 86   11. 99   10. 04  
total cash:  55. 96 M 7. 30 B 7. 05 B
free cash flow:  -21. 40 M 176. 15 M 2. 43 B
operating cash flow:  -36. 53 M 277. 94 M 3. 06 B

book value:  1. 30   15. 06   28. 80  
price/book:  0. 38   -0. 58   -2. 51  
operating margins:  0. 00 % -466. 96 % -635. 17 %
EBITDA margins:  0. 00 % 13. 54 % 22. 51 %
profit margins:  0. 00 % 6. 67 % 10. 02 %
gross margins:  0. 00 % 48. 21 % 54. 28 %

1-yr max volatility:  -37. 04 % --- ---
1-yr mean volatility:  -0. 54 % 0. 01 % 0. 07 %

1-yr EPS:  -1. 33   3. 08   4. 11  
forward EPS:  -0. 92   4. 75   7. 18  
P/E:  -0. 38   15. 54   29. 27  
forward P/E:  -0. 55   -20. 90   3. 33  
PE/G:  0. 01   1. 33   6. 07  
growth:  -64. 38 % 755. 42 % 114. 65 %
earnings high:  -0. 19   1. 33   1. 68  
earnings avg:  -0. 22   0. 97   1. 54  
earnings low:  -0. 24   0. 70   1. 41  
revenue high:  -0. 00   2. 81 B 11. 37 B
revenue avg:  -0. 00   2. 70 B 11. 06 B
revenue low:  -0. 00   2. 61 B 10. 84 B
return on assets:  -30. 51 % -3. 63 % 3. 73 %
return on equity:  -71. 30 % 102. 34 % 26. 90 %

beta (1yr vs S&P500):  0. 87   1. 22   0. 94  
sharpe (1yr):  -1. 54   0. 14   1. 05  

held % insiders:  87. 73 % 6. 40 % 3. 16 %
held % institutions:  0. 00 % 79. 62 % 70. 81 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-22 : LIFE
.        + 0 =             0 :: INITIAL WEIGHT
.  + 382.411 =       382.411 :: inverse volume-to-price addition
.   + 300.21 =       682.621 :: spline projection addition
.  - 190.897 =       491.724 :: poor performance penalty
.     x 0.48 =        236.06 :: one-year gains+dividend factor
.    x 0.975 =        230.07 :: 13 weeks' performance factor
.    x 1.478 =       340.031 :: industry recommendation factor
.    x 1.142 =       388.177 :: symbol recommendation factor
.    x 0.997 =       386.992 :: return on assets factor
.    x 0.993 =       384.233 :: return on equity factor
.     x 2.98 =      1145.144 :: current ratio factor
.    x 1.112 =      1273.647 :: quick ratio factor
.    x 1.138 =      1448.892 :: short ratio factor
.    x 2.004 =      2903.335 :: price-to-book factor
.    x 1.379 =      4004.507 :: debt-to-equity factor
.    x 1.034 =      4141.159 :: EBITDA multiple vs industry factor
.     x 5.59 =     23150.376 :: EBITDA multiple factor
.    x 2.171 =     50268.258 :: P/E weight
.    x 2.209 =    111040.526 :: PE/G factor
.    x 1.634 =    181400.703 :: beta factor
.    x 0.419 =     76095.693 :: sharpe factor
.    x 1.759 =    133864.084 :: target low factor
.    x 1.236 =    165416.151 :: target mean factor
.    x 1.071 =    177112.839 :: target high factor
.    x 1.012 =    179293.446 :: industry 12-weeks return
.    x 0.998 =     179009.66 :: overall "drift" factor
.    x 0.998 =    178708.297 :: largest single-day jump factor
.     x 0.06 =     10713.927 :: low price factor
.      x 1.0 =     10712.816 :: factor hist industry gain for week 07
.   cubeRoot =        22.045 :: reduced for readability
.                     22.045 :: FINAL WEIGHT for NASDAQ:LIFE


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org